The specificity of galectin-3 immuno-PET targeting for imaging thyroid cancer has been further confirmed by an extensive ex vivo biodistribution analysis, measuring the amount of 89Zr-labeled probe accumulated in tumors and normal tissues explanted from the experimental animals [65]. Here, LGALS3 is linked to thyroid gland carcinoma.